Feedback / Questions
sifalimumab (MDX-1103) - AstraZeneca
AZ: Investor Day
(AstraZeneca)
-
Mar 21, 2013 -
Anticipated data from P2 trial for SLE in 2013; Anticipated initiation of P3 trial for SLE in 2014
Anticipated new P3 trial • Anticipated P2 data
•
Immunology • Lupus
http://www.astrazeneca.com/Media/Events-calendar
Mar 21, 2013
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.